
Automation In Biopharma Market
Automation in Biopharma Market Forecasts to 2030 - Global Analysis By Component (Automation Hardware, Automation Software, Services Project Phase, Services Operation Phase, Analytics Automation and Other Components), Mode of Automation, Technology, Application, End User and By Geography
According to Stratistics MRC, the Global Automation in Biopharma Market is growing at a CAGR of 8.4% during the forecast period. Automation in biopharma is the use of advanced technologies and systems to streamline and optimize various processes in the production of biopharmaceuticals. This includes automating tasks such as cell culture, protein production, quality control, data analysis, and packaging. By integrating robotics, artificial intelligence, and machine learning, automation enhances efficiency, reduces human error, improves consistency, and accelerates time-to-market for new drugs. It plays a crucial role in ensuring regulatory compliance and cost-effective manufacturing in the biopharmaceutical industry.
Market Dynamics:
Driver:
Growing demand for personalized medicine
The growing demand for personalized medicine is driving the need for market. Personalized treatments require highly specific and scalable manufacturing processes to cater to individual patient needs, such as gene therapies and customized biologics. Automation facilitates the precise control of these complex processes, ensuring consistency, and efficiency. By enhancing production capabilities and reducing human error, automation enables biopharma companies to meet the increasing demand for tailored therapies, while ensuring high-quality standards.
Restraint:
Data security and privacy concerns
Data security and privacy concerns in biopharma automation can lead to significant risks, including unauthorized access to sensitive patient information, intellectual property theft, and regulatory violations. Breaches may result in reputational damage, costly fines, and loss of trust from stakeholders. Inadequate data protection can also hinder innovation and collaboration, as companies may be reluctant to share critical information, ultimately delaying drug development and affecting market competitiveness.
Opportunity:
Improved data quality and consistency
Improved data quality and consistency in the market enhances decision-making, regulatory compliance, and operational efficiency. By integrating advanced technologies such as AI and machine learning, companies can minimize human errors, streamline data collection, and ensure real-time data accuracy. This leads to more reliable processes, faster drug development, and optimized manufacturing, ultimately accelerating time-to-market and reducing costs while maintaining high standards of quality and safety.
Threat:
High initial investment costs
High initial investment costs in the market can be a significant barrier for smaller companies. The substantial upfront expenses for advanced technologies, equipment, and infrastructure may delay or prevent adoption. This can result in slower innovation, reduced competitiveness, and increased financial pressure. Smaller firms may struggle to secure funding, hindering their ability to scale operations, improve efficiency, and keep pace with larger industry players.
Covid-19 Impact:
The COVID-19 pandemic accelerated the adoption of the market, highlighting the need for faster, more efficient drug development and manufacturing processes. Automation helped streamline vaccine production, clinical trials, and supply chain management. However, the pandemic also disrupted global supply chains, leading to delays and challenges in deploying new technologies. Despite these hurdles, the crisis underscored automation’s role in enhancing resilience and scalability in biopharma operations.
The automation software segment is expected to be the largest during the forecast period
The automation software segment is expected to account for the largest market share during the forecast period. It integrates technologies like AI, machine learning, and data analytics to improve efficiency, reduce errors, and ensure regulatory compliance. By automating repetitive tasks, these software solutions enhance accuracy in data collection, speed up production timelines, and support real-time monitoring. This ultimately leads to lower costs, faster time-to-market, and higher product quality in the biopharma industry.
The pharmaceutical companies segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the pharmaceutical companies segment is predicted to witness the highest growth rate. By integrating automation tools like robotics, AI, and machine learning, they improve accuracy, reduce human error, and speed up production processes. These companies focus on optimizing supply chains, clinical trials, and quality control. Automation not only lowers operational costs but also accelerates innovation, ensuring faster time-to-market for critical therapies and treatments.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share driven by technological advancements and the need for more efficient drug production and development processes. With strong investments in AI, robotics, and data analytics, North American companies are optimizing manufacturing, enhancing quality control, and ensuring regulatory compliance. The region's focus on innovation, coupled with a robust healthcare infrastructure, positions it as a global leader in biopharma automation.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. The growing demand for biologics, biosimilars, and advanced therapies is pushing biopharmaceutical companies to adopt automation technologies to streamline production processes, improve consistency, and meet high production volumes. Additionally, the development of advanced technologies has enhanced automation systems, making them more accessible and adaptable to the biopharmaceutical industry.
Key players in the market
Some of the key players in Automation in Biopharma market include Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher Corporation, GE HealthCare Technologies Inc., PerkinElmer, Inc., Tecan Group Ltd., Sartorius AG, Agilent Technologies, Inc., Hamilton Company, Bio-Rad Laboratories, Inc., Eppendorf AG, Bruker Corporation, Honeywell International Inc., Parker Hannifin Corporation, Rockwell Automation, Inc., Waters Corporation and Yokogawa Electric Corporation.
Key Developments:
In December 2024, Siemens Healthineers has concluded the acquisition from Novartis of Advanced Accelerator Applications Molecular Imaging, a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. The acquired company will be known as Advanced Accelerator Applications, a Siemens Healthineers company.
In June 2024, Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific™ KingFisher™ PlasmidPro Maxi Processor* (PlasmidPro), the only fully automated maxi-scale plasmid DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi scale purification and delivering high-purity plasmid without manual column preparation and intervention.
Components Covered:
• Automation Hardware
• Automation Software
• Services Project Phase
• Services Operation Phase
• Analytics Automation
• Other Components
Mode of Automations Covered:
• Fully Automated Systems
• Semi-Automated Systems
Technologies Covered:
• Automation Technology
• Digitization Technology
Applications Covered:
• Research & Development
• Biomanufacturing
• Clinical Trials
• Quality Control & Assurance
• Diagnostics
• Other Applications
End Users Covered:
• Pharmaceutical Companies
• Biopharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutions
• Laboratories
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Automation in Biopharma Market, By Component
5.1 Introduction
5.2 Automation Hardware
5.3 Automation Software
5.4 Services Project Phase
5.5 Services Operation Phase
5.6 Analytics Automation
5.7 Other Components
6 Global Automation in Biopharma Market, By Mode of Automation
6.1 Introduction
6.2 Fully Automated Systems
6.3 Semi-Automated Systems
7 Global Automation in Biopharma Market, By Technology
7.1 Introduction
7.2 Automation Technology
7.2.1 Process Automation
7.2.2 Laboratory Automation
7.2.3 Robotics and Artificial Intelligence
7.2.4 Control Systems
7.2.5 Programmable Logic Controllers (PLCs)
7.3 Digitization Technology
7.3.1 Data Analytics and Visualization
7.3.2 Electronic Lab Notebooks (ELN)
7.3.3 Cloud Computing
7.3.4 Internet of Things (IoT)
7.3.5 Digital Twin Technology
8 Global Automation in Biopharma Market, By Application
8.1 Introduction
8.2 Research & Development
8.2.1 Drug Discovery
8.2.2 Genomics and Proteomics
8.3 Biomanufacturing
8.3.1 Upstream Processing
8.3.2 Downstream Processing
8.4 Clinical Trials
8.5 Quality Control & Assurance
8.6 Diagnostics
8.7 Other Applications
9 Global Automation in Biopharma Market, By End User
9.1 Introduction
9.2 Pharmaceutical Companies
9.3 Biopharmaceutical Companies
9.4 Contract Research Organizations (CROs)
9.5 Academic and Research Institutions
9.6 Laboratories
9.7 Other End Users
10 Global Automation in Biopharma Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Thermo Fisher Scientific Inc.
12.2 Siemens Healthineers AG
12.3 Danaher Corporation
12.4 GE HealthCare Technologies Inc.
12.5 PerkinElmer, Inc.
12.6 Tecan Group Ltd.
12.7 Sartorius AG
12.8 Agilent Technologies, Inc.
12.9 Hamilton Company
12.10 Bio-Rad Laboratories, Inc.
12.11 Eppendorf AG
12.12 Bruker Corporation
12.13 Honeywell International Inc.
12.14 Parker Hannifin Corporation
12.15 Rockwell Automation, Inc.
12.16 Waters Corporation
12.17 Yokogawa Electric Corporation
List of Tables
1 Global Automation in Biopharma Market Outlook, By Region (2022-2030) ($MN)
2 Global Automation in Biopharma Market Outlook, By Component (2022-2030) ($MN)
3 Global Automation in Biopharma Market Outlook, By Automation Hardware (2022-2030) ($MN)
4 Global Automation in Biopharma Market Outlook, By Automation Software (2022-2030) ($MN)
5 Global Automation in Biopharma Market Outlook, By Services Project Phase (2022-2030) ($MN)
6 Global Automation in Biopharma Market Outlook, By Services Operation Phase (2022-2030) ($MN)
7 Global Automation in Biopharma Market Outlook, By Analytics Automation (2022-2030) ($MN)
8 Global Automation in Biopharma Market Outlook, By Other Components (2022-2030) ($MN)
9 Global Automation in Biopharma Market Outlook, By Mode of Automation (2022-2030) ($MN)
10 Global Automation in Biopharma Market Outlook, By Fully Automated Systems (2022-2030) ($MN)
11 Global Automation in Biopharma Market Outlook, By Semi-Automated Systems (2022-2030) ($MN)
12 Global Automation in Biopharma Market Outlook, By Technology (2022-2030) ($MN)
13 Global Automation in Biopharma Market Outlook, By Automation Technology (2022-2030) ($MN)
14 Global Automation in Biopharma Market Outlook, By Process Automation (2022-2030) ($MN)
15 Global Automation in Biopharma Market Outlook, By Laboratory Automation (2022-2030) ($MN)
16 Global Automation in Biopharma Market Outlook, By Robotics and Artificial Intelligence (2022-2030) ($MN)
17 Global Automation in Biopharma Market Outlook, By Control Systems (2022-2030) ($MN)
18 Global Automation in Biopharma Market Outlook, By Programmable Logic Controllers (PLCs) (2022-2030) ($MN)
19 Global Automation in Biopharma Market Outlook, By Digitization Technology (2022-2030) ($MN)
20 Global Automation in Biopharma Market Outlook, By Data Analytics and Visualization (2022-2030) ($MN)
21 Global Automation in Biopharma Market Outlook, By Electronic Lab Notebooks (ELN) (2022-2030) ($MN)
22 Global Automation in Biopharma Market Outlook, By Cloud Computing (2022-2030) ($MN)
23 Global Automation in Biopharma Market Outlook, By Internet of Things (IoT) (2022-2030) ($MN)
24 Global Automation in Biopharma Market Outlook, By Digital Twin Technology (2022-2030) ($MN)
25 Global Automation in Biopharma Market Outlook, By Application (2022-2030) ($MN)
26 Global Automation in Biopharma Market Outlook, By Research & Development (2022-2030) ($MN)
27 Global Automation in Biopharma Market Outlook, By Drug Discovery (2022-2030) ($MN)
28 Global Automation in Biopharma Market Outlook, By Genomics and Proteomics (2022-2030) ($MN)
29 Global Automation in Biopharma Market Outlook, By Biomanufacturing (2022-2030) ($MN)
30 Global Automation in Biopharma Market Outlook, By Upstream Processing (2022-2030) ($MN)
31 Global Automation in Biopharma Market Outlook, By Downstream Processing (2022-2030) ($MN)
32 Global Automation in Biopharma Market Outlook, By Clinical Trials (2022-2030) ($MN)
33 Global Automation in Biopharma Market Outlook, By Quality Control & Assurance (2022-2030) ($MN)
34 Global Automation in Biopharma Market Outlook, By Diagnostics (2022-2030) ($MN)
35 Global Automation in Biopharma Market Outlook, By Other Applications (2022-2030) ($MN)
36 Global Automation in Biopharma Market Outlook, By End User (2022-2030) ($MN)
37 Global Automation in Biopharma Market Outlook, By Pharmaceutical Companies (2022-2030) ($MN)
38 Global Automation in Biopharma Market Outlook, By Biopharmaceutical Companies (2022-2030) ($MN)
39 Global Automation in Biopharma Market Outlook, By Contract Research Organizations (CROs) (2022-2030) ($MN)
40 Global Automation in Biopharma Market Outlook, By Academic and Research Institutions (2022-2030) ($MN)
41 Global Automation in Biopharma Market Outlook, By Laboratories (2022-2030) ($MN)
42 Global Automation in Biopharma Market Outlook, By Other End Users (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY

We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?

Assured Quality
Best in class reports with high standard of research integrity

24X7 Research Support
Continuous support to ensure the best customer experience.

Free Customization
Adding more values to your product of interest.

Safe & Secure Access
Providing a secured environment for all online transactions.

Trusted by 600+ Brands
Serving the most reputed brands across the world.